<DOC>
	<DOCNO>NCT01917708</DOCNO>
	<brief_summary>This single arm phase I study assess tolerability abatacept combine cyclosporine mycophenolate mofetil graft versus host disease prophylaxis child undergo unrelated hematopoietic stem cell transplant serious non-malignant disease well assess immunological effect abatacept .</brief_summary>
	<brief_title>BMT Abatacept Non-Malignant Diseases</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation ( HSCT ) represent viable cure child suffer wide variety rare , serious non-malignant disease , Fanconi Anemia , Hurler syndrome , hemophagocytic lymphohistiocytosis . A major obstacle success HSCT morbidity mortality graft versus host disease ( GVHD ) , drive donor T cell recognize react disparate host antigen . This trial conduct step toward test long-term hypothesis costimulation blockade agent abatacept added standard post-transplant GVHD prophylaxis regimen , cyclosporine mycophenolate mofetil , improve disease-free survival unrelated hematopoietic stem cell transplantation ( HSCT ) use reduce intensity condition child non-malignant disease ( NMD ) . This study follow Specific Aims : Specific Aim # 1 : To conduct multicenter pilot assess tolerability abatacept ( n=20 ) . Patients receive four dos ( 10 mg/kg IV day -1 , +5 , +14 +28 ) , schedule well tolerated adolescent adult hematologic malignancy previous pilot . Abatacept combine cyclosporine mycophenolate mofetil . Specific Aim # 2 : To examine immunological effect abatacept set . Three reduced intensity conditioning regimens show effective achieving sustain engraftment patient non-malignant disease available use , depend patient 's disease : - Patients Fanconi anemia receive fludarabine , low dose cyclophosphamide , anti-thymocyte globlulin . - Patients severe aplastic anemia receive low dose total body irradiation , fludarabine , cyclophosphamide , anti-thymocyte globlulin . - Patients NMD receive either low dose total body irradiation regimen alemtuzmab , fludarabine , thiotepa , melphalan regimen .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<mesh_term>Dyskeratosis Congenita</mesh_term>
	<mesh_term>Chediak-Higashi Syndrome</mesh_term>
	<mesh_term>Thrombasthenia</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Lipomatosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Must age 021 year time admission transplant . Must one follow disease : 1 . Glanzmann thrombasthenia 2 . WiskottAldrich syndrome combine immune deficiency 3 . Chronicgranulomatous disease 4 . Severe congenital neutropenia ( resistance GCSF chronic requirement GCSF dose â‰¥10 mcg/kg ) 5 . Leukocyte adhesion deficiency 6 . ShwachmanDiamond syndrome 7 . DiamondBlackfan anemia ( ( transfusion dependent , include steroid failure inability wean steroid ) 8 . Thalassemia major 9 . Fanconi anemia 10 . Hemophagocytic lymphohistiocytosis ( inherit acquire refractory therapy recurrent episode hyperinflammation ) 11 . Dyskeratosiscongenita 12 . Hurler Syndrome 13 . ChediakHigashi syndrome 14 . Acquired ( immune ; noninherited , noncongenital ) severe aplastic anemia 15 . Other inherited congenital marrow failure syndrome complicate severe aplastic anemia 16 . Other inherited congenital red blood cell disorder require monthly chronic transfusion therapy . 17 . Congenital platelet disorder require frequent platelet transfusion ( patient must receive least 10 transfusion last 3 year ) . 18 . Other inherited congenital granulocyte disorder result least three inpatient hospitalization past three year infection . 19 . SCD ( Hgb SS SBeta 0 thalassemia ) eligible age 3 9.99 severe disease . Patients meet one follow criterion qualify severe SCD : ( ) Previous clinical stroke , evidence neurological deficit lasting longer 24 hour , accompany radiographic evidence ischemic brain injury cerebral vasculopathy . ( ii ) Asymptomatic cerebrovascular disease , evidence one following : 1 . Progressive silent cerebral infarction , evidence serial MRI scan demonstrate development succession lesion ( least two temporally discreet lesion , measure least 3 mm great dimension recent scan ) enlargement single lesion , initially measure least 3 mm ) . Lesions must visible T2weighted MRI sequence . 2 . Cerebral arteriopathy , evidence abnormal TCD testing ( confirm elevate velocity single vessel TAMMV &gt; 200 cm/sec nonimaging TCD ) significant vasculopathy MRA ( great 50 % stenosis &gt; 2 arterial segment complete occlusion single arterial segment ) . ( iii ) Frequent ( great equal 3 per year precede 2 year ) painful vasoocclusive episode ( defined episode last great equal 4 hour require hospitalization outpatient treatment parenteral opioids ) . If patient hydroxurea use associate decrease frequency episode , frequency gauge 2 year prior start drug . ( iv ) Recurrent ( great equal 3 lifetime ) acute chest syndrome event necessitate erythtocyte transfusion therapy . ( v ) Any combination great equal 3 acute chest syndrome episode vasoocclusive pain episode ( define ) yearly 3 year . If patient hydroxurea use associate decrease frequency episode , frequency gauge 3 year prior start drug . Must unrelated adult donor ( marrow PBSC ) match least seven eight HLA allele ( A , B , C , DRB1 ; mismatch allele antigen level ) * unrelated cord blood unit match least seven eight locus ( A , B C antigen levelDRB1 allele level ) provide minimum precryopreservation TNC dose 7.5 x 107 TNC/kg recipient weight . Mismatches DRB1 locus may antigen allele level . Human leukocyte antigen ( HLA ) match related donor . Severe combine immune deficiency . Bridging ( portal portal ) fibrosis cirrhosis liver . Pulmonary : DLCO ( correct hemoglobin ) , FEV1 FVC &lt; 40 % predict . In child unable perform pulmonary function testing , chronic need supplemental oxygen serve exclusionary criterion . Severe renal dysfunction define estimate GFR &lt; 60 ml/min/1.73m2 . Severe cardiac dysfunction define shorten fraction &lt; 25 % . Neurologic impairment hemiplegia , define fullscale IQ le equal 70 , quadriplegia paraplegia , inability ambulate , impairment result decline Lansky performance score &lt; 70 % . Clinical stroke within 6 month anticipate transplant . Karnofsky Lansky functional performance score &lt; 50 % HIV infection . Uncontrolled viral , bacterial , fungal protozoal infection time study enrollment . Patient unspecified chronic toxicity serious enough detrimentally affect patient 's capacity tolerate bone marrow transplantation . Patient patient 's guardian ( ) unable understand nature risk inherent blood marrow transplant process . History noncompliance severe enough estimation treat team preclude patient undergo unrelated donor transplantation . Patient pregnant lactating Patients HLA antibody test demonstrates antibody direct disparate HLA molecule .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>non malignant condition</keyword>
	<keyword>blood marrow transplant</keyword>
</DOC>